Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach

Abstract: Type 2 diabetes is a progressive disease with a complex and multifactorial pathophysiology. Patients with type 2 diabetes show a variety of clinical features, including different “phenotypes” of hyperglycemia (eg, fasting/preprandial or postprandial). Thus, the best treatment choice is sometimes difficult to make, and treatment initiation or optimization is postponed. This situation may explain why, despite the existing complex therapeutic armamentarium and guidelines for the treatment of type 2 diabetes, a significant proportion of patients do not have good metabolic control and at risk of developing the late complications of diabetes. The Italian Association of Medical Diabetologists has developed an innovative personalized algorithm for the treatment of type 2 diabetes, which is available online. According to the main features shown by the patient, six algorithms are proposed, according to glycated hemoglobin (HbA1c, ≥9% or ≤9%), body mass index (≤30 kg/m² or ≥30 kg/m²), occupational risk potentially related to hypoglycemia, chronic renal failure, and frail elderly status. Through self-monitoring of blood glucose, patients are phenotyped according to the occurrence of fasting/preprandial or postprandial hyperglycemia. In each of these six algorithms, the gradual choice of treatment is related to the identified phenotype. With one exception, these algorithms contain a stepwise approach for patients with type 2 diabetes who are metformin-intolerant. The glycemic targets (HbA1c, fasting/preprandial and postprandial glycemia) are also personalized. This accessible and easy to use algorithm may help physicians to choose a personalized treatment plan for each patient and to optimize it in a timely manner, thereby lessening clinical inertia. Keywords: type 2 diabetes, treatment guidelines, personalized treatment, Italian Association of Medical Diabetologists, Italian algorithm

Need for a personalized treatment algorithm for type 2 diabetes

There has been an alarming increase in the number of patients with type 2 diabetes (T2D) in recent years, mainly due to the increased prevalence of the disease in adults aged 20–79 years. The International Diabetes Federation predicts that there will be 552 million people with T2D by 2030 if urgent action is not taken.1

T2D is a progressive disease with a complex and multifactorial pathophysiology, and should be assessed and addressed in each individual with T2D.2,3 Control of glucose and other risk factors, including dyslipidemia and hypertension, should be achieved as soon as possible in order to avoid the late complications of diabetes and to maintain metabolic control benefits with time, ie, the known “legacy effect”.4,5 In addition to insulin, nowadays we have a complex armamentarium of both oral and injectable antidiabetic agents.6,7
Each therapeutic drug class addresses different pathogenic mechanisms of T2D. Further, within each class, there are pharmacological compounds with peculiarities in terms of their pharmacodynamic and pharmacokinetic actions, resulting in some advantages and/or disadvantages, limitations, and adverse effects. In addition, there are new drugs in various stages of development within the existing pharmacological classes used to treat T2D, and other therapeutic classes are emerging. Today, seven therapeutic classes of antidiabetic agents are available, ie, biguanides (metformin only), insulin secretagogues (sulfonylureas and glinides), α-glucosidase inhibitors, thiazolidinediones, incretin-based drugs (dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists), sodium-glucose cotransporter 2 inhibitors, and insulin.

The international and national guidelines for the treatment of T2D establish a target glycated hemoglobin (HbA\textsubscript{1c}) value (eg, <7%) as in the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes, which should be individualized. These guidelines recommend lifestyle modification and, if not contraindicated, metformin either from the very beginning or if the patient has failed to reach their target HbA\textsubscript{1c} with lifestyle intervention. Even if metabolic control is initially achieved, it is likely deteriorate over time because T2D is a progressive disease, and there will be a need for intensification of treatment. Accordingly, after failure of metformin monotherapy, the current guidelines recommend addition of a second and then a third drug (oral or injectable), to be chosen from the other classes, taking into account the complementary mechanism of action, efficacy, durability, glycemic effects (action is predominantly on fasting plasma glucose or postprandial glucose), extraglycemic effects, safety (not limited just to hypoglycemia and weight gain), simplicity, and costs. Only these considerations make combinations of agents possible, which are considerably more if we include all the therapeutic options that exist in each class (eg, insulin or incretin-based therapy, such as dipeptidyl peptidase 4 inhibitors or glucagon-like peptide 1 receptor agonists). Choosing between antidiabetic drug combinations becomes even more difficult when individual variables are taken into account, such as patient age, duration of diabetes, presence of microvascular and macrovascular diabetic complications, existence of comorbidities like cardiovascular disease or renal failure, the risk of hypoglycemia, cognitive and socioeconomic status of the patient, patient preferences, compliance, and life expectancy. The “glycemic pattern”, which defines the “phenotype” of the patient, is also important for achieving predetermined glycemic targets. Indeed, according to Monnier et al, the contribution of postmeal and fasting glucose is approximately equal at an HbA\textsubscript{1c} of 7.5%; however, at HbA\textsubscript{1c} levels \(\leq 7.5%\) the contribution of postprandial glucose increases progressively with decreasing HbA\textsubscript{1c} levels and conversely, at levels of HbA\textsubscript{1c} \(\geq 7.5%\), the contribution of fasting plasma glucose predominates.

It is noteworthy that not all the possible drug combination choices are supported by meta-analysis of randomized controlled trials or even by randomized controlled trials themselves, as acknowledged by the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Therefore, we agree with the position statement that “many clinicians are therefore perplexed as to the optimal strategies for their patients”. T2D is treated not only by diabetologists and endocrinologists, but also by other specialists and general practitioners, and the current guidelines include these physicians as their target audience. Given the situation described above, the longstanding need for implementation of clinical practice guidelines as evidence-based algorithms is not surprising. However, what is surprising is that, despite the existing comprehensive armamentarium and guidelines for the treatment of T2D, a significant proportion of patients do not have good metabolic control. The existing guidelines:

- outline the available therapeutic options for T2D, along with their mechanism of action, advantages, and disadvantages/side effects, as well as their possible combinations, presenting practitioners with multiple choices to make
- set a “general” HbA\textsubscript{1c} target, even if some acknowledge that this target should be individualized
- with some exceptions, indicate that the HbA\textsubscript{1c} level at entry does not influence treatment choices
- recommend lifestyle modification and metformin as initial steps; after metformin failure, not all possible combinations of recommended drugs are evidence-based
- put cost as a priority in selection of medication, prioritizing sulfonylureas as a second-line therapy
- recommend initiation of insulin using a basal or premixed insulin, and seldom with a meal-time rapid-acting insulin
- do not recommend routine self-monitoring of blood glucose for T2D not treated with insulin
- suggest that need for treatment intensification be evaluated every 3–6 months.

Over time, the guidelines have been updated due to advances in the treatment of T2D, in response to criticism, or to meet the need for a more practical, personalized.
approach. Other national guidelines/ algorithms have been born of the same need. Relevant examples include the Finnish Current Care Guideline for Diabetes17,18 and the algorithm released by the Italian Association of Medical Diabetologists (AMD) in the European Union,22 and the computer-assisted decision support tool now available in the USA.23

**Interactive therapeutic algorithm proposed by the AMD**

The UK Prospective Diabetes Study4 clearly showed a benefit of intensive glycemic control with regard to the microvascular complications of diabetes, but its results were inconclusive for macrovascular complications. Further, the more recent ACCORD (Action to Control Cardiovascular Risk in Diabetes),24 ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN Controlled Evaluation),25 and VADT (Veterans Affairs Diabetes Trial)26 studies reported unfavorable results from intensive glycemic control. The ACCORD trial was terminated prematurely due to a higher overall mortality in the intensively treated group versus the conventionally treated group, and ADVANCE and VADT showed that intensive control of glycemia had no significant benefit in decreasing the risk of an adverse cardiovascular outcome.

Recognizing that patients with T2D in the UK Prospective Diabetes Study were newly diagnosed, without diabetes related-complications, and younger at enrolment in comparison with those included in ACCORD, ADVANCE, and VADT, who had a long history of disease and established macrovascular complications at enrolment, the medical community proposed individualized HbA1c targets and treatment for patients with T2D.

Young or relatively young patients with recent onset of T2D and minimal or no microvascular or macrovascular complications will benefit the most from tight glycemic control, keeping blood glucose levels as close to normal as possible. On the other hand, older patients with a longer history of diabetes and late complications of diabetes, in particular cardiovascular disease, will have higher targets that are individualized to each particular set of circumstances. These individualized targets may be adapted in response to changes in the health status or life of the individual.27-28 Eldor and Raz proposed a target HbA1c <6.5% for “low risk/high benefit” patients, <7% for “intermediate risk/intermediate benefit” patients, and 7.5%–8% for “high risk/low benefit” patients.29

**Finnish guideline**

The current guideline for care of T2D in Finland is an algorithm available online and can be easily updated.

Each T2D patient may best fit into one of the six available “main features”, ie, early diabetes, chronic diabetes with a history of more than 10 years, morbid obesity, elderly, employed in transport industry, and impaired kidney function. It also contains hyperlinks to each drug class database with concise “strengths and opportunities” on the one hand and “weaknesses and threats” on the other. Based on the risk to benefit assessment, this algorithm indicates the choice of treatment, ie, good, not as a first choice or contraindicated, and careful follow-up.17,28 Important conditions related to the patient are also taken into consideration.

**Computer-assisted decision support tool**

This program was first presented in 200530 and updated twice since.23,31 As suggested by its name, the computer-assisted decision support tool can be used by general practitioners for decision making and has been implemented in some centers in the USA. The most recent version considers 69 regimens with combinations of up to four antidiabetic drugs. Patients can enter their self-monitored blood glucose values into the system and the software analyzes and interprets these data according to glycemic targets. The tool also generates a treatment recommendation that can be accepted or not by the general practitioner. Its authors stress that the clinical judgment and experience of the physician should prevail because the program (like any other) may generate errors. The program will be updated in the future to accommodate certain special populations, eg, the elderly and women with gestational diabetes.

**AMD algorithm**

**Introduction**

Based on previous publications that have attempted to individualize the treatment of T2D32-34 and the above-mentioned Finnish guideline for T2D, in 2011 the AMD released a web-based algorithm available in both Italian and English.22 The initial version was published in a peer-reviewed journal in 2012, to which the reader is referred for details regarding the algorithm.35 Since then, the AMD algorithm has been reviewed and updated twice. The last update in May 2013 was done in consultation with the Italian College of General Practitioners and was undertaken in response to the needs and concepts published on T2D treatment36 and to include newly approved drugs or expanded indications for existing ones in the European Union.37 New targets for postprandial glucose have been included according to the guidelines published by the International Diabetes Federation,36 a new class of agents
for the treatment of T2D (sodium-glucose cotransporter 2 inhibitors) has been introduced, and the indications for and dosing of dipeptidyl peptidase 4 inhibitors in patients with chronic renal impairment have been updated.\(^5\)

A new table (Table 1) has been added describing the hypoglycemic effects on fasting plasma glucose, postprandial glucose, side effects, and costs of all approved therapeutic classes of glucose-lowering agents in the European Union by the time of revision and update of the algorithms.\(^7\) In this third version, a separate table (Table 2) is proposed for incretins and sodium-glucose cotransporter 2 inhibitors, with recommended combinations including these agents.\(^7\) Further, two new subcategories of T2D patients are included, ie, those who are metformin-intolerant (Figure 2 algorithms B-F) and elderly frail patients (Figure 2 algorithm F).

**Glycemic targets: HbA\(_{1c}\) and glycemia**

In order to minimize the risk of hypoglycemia, the HbA\(_{1c}\) target has been individualized based on the age of the patient (young adult \(\leq 45\) years, adult \(\geq 45\) and \(\leq 70\) years, and elderly \(\geq 70\) years) and on the presence of macrovascular complications of diabetes and comorbidities.

A more stringent HbA\(_{1c}\) target of \(< 6.5\%\) is set for young adults with or without these complications and/or comorbidities; however, elderly individuals (\(\geq 70\) years) with macrovascular complications and/or comorbidities have an HbA\(_{1c}\) target of 7\%–8\% (Figure 1). In this age group, biological age, frailty, and glomerular filtration rate have to be carefully evaluated at the start of treatment, and thereafter periodically, according to the judgment of the clinician. For an HbA\(_{1c}\) target \(\leq 7\%\), glycemic values are fixed at 70–115 mg/dL (3.9–6.4 mmol/L) for fasting/preprandial blood glucose and at \(\leq 160\) mg/dL (8.9 mmol/L) for postprandial blood glucose. For an HbA\(_{1c}\) target \(> 7\%\), both fasting/preprandial and postprandial glycemic targets are set by the clinician, taking into account the individual characteristics of the patient in order to avoid hypoglycemia.

**Table 1** All approved classes of glucose lowering agents in the European Union by the time of review and update of the algorithms (April 2013) are set out, describing their hypoglycemic properties on fasting plasma glucose, postprandial glucose, side effects, and costs

<table>
<thead>
<tr>
<th>Properties of currently available blood glucose lowering agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGIs</strong></td>
</tr>
<tr>
<td><strong>Effect on fasting glucose</strong></td>
</tr>
<tr>
<td><strong>Effect on postprandial glucose</strong></td>
</tr>
<tr>
<td><strong>Weight</strong></td>
</tr>
<tr>
<td><strong>Hypoglycemia in monotherapy</strong></td>
</tr>
<tr>
<td><strong>CV outcome studies</strong></td>
</tr>
<tr>
<td><strong>CHD benefit</strong></td>
</tr>
<tr>
<td><strong>GI side-effects</strong></td>
</tr>
<tr>
<td><strong>Other side-effects/concerns</strong></td>
</tr>
<tr>
<td><strong>Cost</strong></td>
</tr>
<tr>
<td><strong>Experience with the medicine</strong></td>
</tr>
</tbody>
</table>

**Notes:** Effect: 0 = neutral; ++ = mild; ++ = moderate; +++ = moderate to marked; ++++ = marked; --effect: 0 = favorable; 0 = neutral; ++ = mild gain; ++ = moderate gain; +++ = moderate to marked gain; ++++ = marked gain. \(^4\)Risk: 0 = neutral; ++ = mild; +++ = moderate to marked; ++++ = marked; CV outcome studies, GI side-effects: + = present, - = not present, ± not assoc, with CV risk/results of CV outcome trials expected; ++cost = cheap; ++ = quite cheap; +++ = expensive; +++ = very expensive; experience: ++ very small; ++ small; +++ high; ++++ very high; -- new drug. Summary of product characteristics of each drug in the therapeutic class with link to the European Medicines Agency. Copyright © 2013 AMD. Reproduced with permission from [http://www.servmedi.it/algoritmi_en_2013/images/tabella_1.jpg](http://www.servmedi.it/algoritmi_en_2013/images/tabella_1.jpg).

**Abbreviations:** AMD, Associazione Medici Diabetologi (Italy); AGIs, alpha-glucosidase inhibitors; SUs, sulphonylureas; TZDs, thiazolidinediones; DPP4i, dipeptidyl peptidase 4 inhibitors; GLP-1 RA, glucagon-like peptide-1 receptor agonists; CV, cardiovascular; CHD, coronary heart disease; CHF, congestive heart failure; GI, gastrointestinal; URT, upper respiratory tract; UT, urinary tract; GU, genitourinary.
Table 2  Recommended associations (by the time of review and update of the algorithms in April 2013) of incretins and SGLT-2i are shown

<table>
<thead>
<tr>
<th>Permitted combinations with DPP4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MoN</strong></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Sita int Mf</td>
</tr>
<tr>
<td>Vilda int Mf</td>
</tr>
<tr>
<td>Saxa</td>
</tr>
<tr>
<td>Lina int o ci Mf</td>
</tr>
<tr>
<td>Dapa, int o ci Mf</td>
</tr>
<tr>
<td>Exe</td>
</tr>
<tr>
<td>Exe LAR</td>
</tr>
<tr>
<td>Lira</td>
</tr>
<tr>
<td>Lixi</td>
</tr>
</tbody>
</table>

**Note:** 1) Prescribed generically in combination with other oral hypoglycemic agents, including insulin. 2) But with metformin + pioglitazone = yes. 3) There are no explicit indications for sulphonylurea alone, but for metformin + sulphonylurea = yes. 4) Basal insulin alone. 5) Copyright © 2013 AMD. Reproduced with permission from http://www.aemmedi.it/algoritmi_en_2013/images/diapo78_algoritmi.jpg.

**Abbreviations:** AMD, Associazione Medici Diabetologi (Italy); SGLT-2i, sodium-glucose cotransporter type 2 inhibitors; Y, yes; N, no; Mf, metformin; Su, sulphonylurea; Pio, pioglitazone; Rep, repaglinide; Agi, alpha-glucosidase inhibitors (acarbose); Ins, insulin; Sita, sitagliptin; Vilda, vildaglaptin; Saxa, Saxagliptin; Lina, Linagliptin; Dapa, dapagliflozin; Exe, exenatide; Exe LAR, exenatide long-acting release; Lira, Liraglutide; Lixi, Lixisenatide; int, intolerance; ci, contraindications; NS, not studied.

- intensive, ie, seven glycemic measurements per day for 3 consecutive days (before and 2 hours after main meals and at bed time).
- staggered, ie, monitoring blood glucose before and 2 hours after breakfast on the first day, before and 2 hours after lunch, and before and 2 hours after the evening meal on the third day; this cycle is repeated until the end of the week.
- self-monitoring of blood glucose five times daily over 3 consecutive days (monitoring blood glucose before breakfast and the evening meal, and 2 hours after the three main meals).

**Parameters for the characterization of patients with type 2 diabetes**

**Age (years)**

- **Young adults** <45
- **Adults** ≥45 and <70
- **Elderly** ≥70

**Presence of comorbidities/macrovacular complications**

- **NO**
- **YES**

**Target HbA1c** **mmol/mol (%)**

- <48 (<6.5)
- ≤48 (<6.5)
- >48 and ≤53 (>6.5 and ≤7)
- ≤53 (>7)
- ≥53 and ≤64 (>7 and ≤8)

**Figure 1** HbA1c target has been individualized based on the age of the patient and on the presence of macrovascular diabetes complications/co-morbidities.

**Notes:** 1) Carefully evaluate (at presentation and over the course of time) glomerular filtration rate (GFR), potential hypoglycemia risks (with particular care in the use of sulphonylures or glinides), nutritional status, and presence of comorbidities/frailty. 2) The HbA1c target values proposed are intended as safe objectives, limiting the risk of hypoglycemia.

**Abbreviation:** HbA1c, glycated hemoglobin.
The treating physician in consultation with the patient should establish judiciously both the best scheme of self-monitoring to be used and the period of time involved (eg, the week preceding the consultation) in order to obtain useful information, taking into account patient convenience and minimization of costs. Self-monitoring of blood glucose allows two main types of hyperglycemia or patient phenotypes to be recognized, ie, predominantly fasting/preprandial (>60% of fasting/before-meal values indicating hyperglycemia) and predominantly postprandial (>60% of measurements taken 2 hours after a meal indicating hyperglycemia). The antidiabetic agent (oral or injectable) and insulin are initiated, and then intensified according to the patient phenotype, noting that insulin treatment does not exclude rapid-acting compounds.

Main subcategories seen in clinical practice

The Italian algorithm takes into account some individual variables and characteristics as follows:

- an initial HbA1c value, ie, a cut-off point of 9%, has been chosen, leading to subcategories and consequently to different therapeutic options
- BMI <30 kg/m² and ≥30 kg/m²
- occupations associated with a risk of hypoglycemia, such as workers at high altitude, pilots, drivers, crane operators, and platform workers
- presence of chronic renal failure
- frail elderly status

According to the main features of the patient, there are six main subcategories (Figure 2). Each flowchart refers to newly diagnosed patients and/or those who are not receiving anti-diabetic treatment. For other cases, the algorithm at the level nearest to the patient’s characteristics should be considered. With the exception of the algorithm in Figure 2, which refers to patients with high glucose and HbA1c ≥9%, who are treated with lifestyle intervention ± insulin, these algorithms (Figure 2) also contain separate treatment recommendations for patients who are metformin-intolerant.

Other important considerations

In all subcategories (Figure 2), treatment starts with lifestyle intervention, ie, diabetes education, physical activity, and medical nutritional therapy. We support the recommendation to intervene on lifestyle first for two reasons, the most obvious one being linked to the importance of education and motivation to modify lifestyle at this stage of the disease, and the other relating to the fact that often, previous nutritional habits may have been so wrong and “absurd” that frank improvement is possible even without drugs. In this situation, after 1–3 months, along with lifestyle interventions, the next therapeutic step includes antidiabetic agents and/or insulin. Insulin treatment may started at any level, even temporarily, according to the judgment of the treating physician, bearing in mind the risk to benefit ratio and costs, eg, weight gain in obese patients and hypoglycemia in frail elderly patients. It is also recommended to step back in the treatment algorithm when necessary.

Target body weight is also individualized in this algorithm. For overweight patients, the aim is to reach and maintain the ideal weight whenever possible. For obese and extremely obese patients, structured lifestyle intervention guided by a multidisciplinary team (diabetologist, dietician, diabetes educator) and a 5%–10% decrease in initial body weight (or at least stabilization of weight) are recommended. Bariatric surgery may also considered be for patients with a body mass index >35 kg/m².

Finally, it is worth stressing that the decision process related to each therapeutic level is complex and individualized, and is based on the best knowledge, experience, and judgment of the treating physician, keeping in mind the efficacy of the treatment and patient safety. This algorithm guides the physician through the multiple possible choices of antidiabetic agent (including insulin) or combinations thereof according to the patient’s phenotype.

**Figure 2** The Italian algorithm.

**Notes:** The Italian algorithm takes into account some individual variables/main features: initial value of HbA1c; BMI, <30 kg/m² and ≥30 kg/m²; professions associated with hypoglycemia risk such as work at high altitude, pilots, drivers, crane machinists, platform workers, etc; presence of chronic renal failure; frailty of elderly T2D patients. Copyright © 2013 AMD. Reproduced with permission from [http://www.ammmed.it/algorithmi_en_2013/algorithmi.html](http://www.ammmed.it/algorithmi_en_2013/algorithmi.html).

**Abbreviations:** AMD, Associazione Medici Diabetologi (Italy); BMI, body mass index; CRF, chronic renal failure; HbA1c, glycated hemoglobin.
Conclusion

Given that T2D patients are heterogeneous in their clinical features and that T2D is a progressive disease, there is a clinical need for a personalized algorithm that covers these issues. The Italian algorithm for the treatment of T2D is an innovative, accessible, and easy to use dedicated online tool for doctors who treat patients with the disease. It is innovative in that patients can be easily fitted into a clinical category and phenotyped, and the gradual treatment is easy to follow as diabetes progresses. This tool may counteract clinical inertia, and by getting more patients to their fixed targets and reducing long-term complications, may lessen the burden of T2D and its related costs.

Author contributions

AC and MG wrote the manuscript. RC, ADM, KE, SG, and GM revised, read, and approved the final manuscript. The authors take full responsibility for the content of this paper. AC and MG serve as guarantors. SG contributed to this article on behalf of the AMD and GM on behalf of the Italian Society of General Medicine.

Disclosure

AC, MG, RC, ADM, KE, SG, and GM have received consultancy fees, attended advisory board meetings, or have given lectures for a number of pharmaceutical companies producing antidiabetic drugs.

References


